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AS160 (Akt substrate of 160 kDa) is a Rab GTPase-activating
protein implicated in insulin control of GLUT4 (glucose
transporter 4) trafficking. In humans, a truncation mutation
(R363X) in one allele of AS160 decreased the expression of
the protein and caused severe postprandial hyperinsulinaemia
during puberty. To complement the limited studies possible in
humans, we generated an AS160-knockout mouse. In wild-type
mice, AS160 expression is relatively high in adipose tissue
and soleus muscle, low in EDL (extensor digitorum longus)
muscle and detectable in liver only after enrichment. Despite
having lower blood glucose levels under both fasted and random-
fed conditions, the AS160-knockout mice exhibited insulin
resistance in both muscle and liver in a euglycaemic clamp
study. Consistent with this paradoxical phenotype, basal glucose
uptake was higher in AS160-knockout primary adipocytes and
normal in isolated soleus muscle, but their insulin-stimulated
glucose uptake and overall GLUT4 levels were markedly
decreased. In contrast, insulin-stimulated glucose uptake and
GLUT4 levels were normal in EDL muscle. The liver also
contributes to the AS160-knockout phenotype via hepatic insulin
resistance, elevated hepatic expression of phosphoenolpyruvate
carboxykinase isoforms and pyruvate intolerance, which are
indicative of increased gluconeogenesis. Overall, as well as its
catalytic function, AS160 influences expression of other proteins,
and its loss deregulates basal and insulin-regulated glucose
homoeostasis, not only in tissues that normally express AS160,
but also by influencing liver function.
Key words: Akt substrate of 160 kDa (AS160), glucose transport,
insulin resistance, liver, muscle.
INTRODUCTION
Insulin-regulated disposal of glucose from the bloodstream
into skeletal muscle and fat tissues is mediated by the
glucose transporter GLUT4, which undergoes translocation from
intracellular storage sites on to the cell surface upon insulin
stimulation [1]. The insulin-activated PI3K (phosphoinositide 3-
kinase)/PKB (protein kinase B, also known as Akt) signalling
axis plays a key role in mediating insulin-stimulated GLUT4
trafficking (reviewed in [2]). Hunting for substrate(s) downstream
of PKB in controlling GLUT4 trafficking has been the focus of
research in the field for decades. Thus far, the most convincing
substrate is the Rab GAP (GTPase-activating protein) AS160
(Akt substrate of 160 kDa), that was first identified as a PKB/Akt
substrate [3]. Insulin can promote phosphorylation of AS160 on
multiple sites, including Ser318, Ser341, Ser570, Ser588, Thr642, Ser666
and Ser751 [3,4]. Subsequently, phosphorylated AS160 interacts
with the 14-3-3 family of phosphoprotein-binding proteins, which
is mainly mediated by phosphorylated Thr642 [4,5].
Knocking down AS160 in 3T3-L1 adipocytes increased the
cell-surface expression of GLUT4 in the basal state [6,7], whereas
overexpression of an AS160-4P mutant (in which Ser318, Ser588,
Thr642 and Ser751 are substituted by non-phosphorylatable alanine)
in both 3T3-L1 adipocytes [3] and L6 myocytes [8] could inhibit
insulin-stimulated GLUT4 translocation on to the cell surface.
Overexpression of the AS160-4P mutant in 3T3-L1 adipocytes
impaired GLUT4 exocytosis, but not its endocytosis [9]. However,
the exact site in GLUT4 exocytosis that AS160 affects has
not yet been fully resolved. Although some data suggested
that overexpression of the AS160-4P mutant affected exit of
GLUT4 vesicles from the intracellular storage sites [9], other
studies proposed that overexpression of the AS160-4P mutant
affected the docking step of GLUT4 translocation in 3T3-L1
adipocytes [10,11]. When the AS160–14-3-3 interaction was
disrupted through a point mutation in a knockin mouse (in which a
non-phosphorylatable alanine residue replaces Thr642 on AS160),
insulin-stimulated GLUT4 trafficking and glucose uptake was
impaired in muscle, which consequently rendered the AS160
knockin mouse less sensitive to insulin [12]. These studies suggest
that AS160 is involved in retaining GLUT4 within the cytosol,
whereas AS160 phosphorylation and its binding to 14-3-3 is
required for insulin to stimulate GLUT4 translocation on to the
cell surface (reviewed in [13,14]). At least in the in vitro assay,
AS160 possesses RabGAP activity towards downstream small G-
protein Rabs 2A, 8A, 10 and 14 [15]. It has also been proposed that
AS160 regulates GLUT4 trafficking through controlling Rab10 in
3T3-L1 adipocytes [16,17] and Rab8A in L6 myocytes [18].
Previously a premature stop mutation (R363X) on AS160
was identified in human patients with extreme postprandial
hyperinsulinaemia [19]. Owing to limitations in studying humans,
the effects of AS160 deficiency on glucose metabolism in adipose
tissue and skeletal muscle have not been studied. Therefore we
Abbreviations used: AS160, Akt substrate of 160 kDa; EDL, extensor digitorum longus; FBP-1, fructose-1,6-bisphosphatase 1; GAP, GTPase-activating
protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GIR, glucose infusion rate; GLUT, glucose transporter; GSK3, glycogen synthase kinase 3;
MBP, myelin basic protein; PCK/PEPCK, phosphoenolpyruvate carboxykinase; PKB, protein kinase B; PM, plasma membrane; RER, respiratory exchange
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decided to generate an AS160-knockout mouse model to study
how AS160 deficiency affects glucose metabolism.
MATERIALS AND METHODS
Materials
Recombinant human insulin was from Novo Nordisk and
glucose was from Baxter Clintec. Collagenase (Type I) was
from Worthington. Microcystin-LR was from Professor Linda
Lawton (School of Life Sciences, Robert Gordon University,
Aberdeen, U.K.), protease inhibitor cocktail tablets were from
Roche Diagnostics and precast NuPAGE® Bis-Tris gels were
from Invitrogen. Protein G–Sepharose was from GE Healthcare.
2-deoxy-D-[1,2-3H(N)]glucose and D-[1-14C]mannitol were from
PerkinElmer. All other chemicals were from BDH Chemicals or
Sigma–Aldrich.
Antibodies
A rabbit antibody against the C-terminus of AS160 (catalogue
number 07-741) was from Upstate/Millipore. A sheep antibody
against the N-terminus (amino acids 1–280) of AS160 termed
anti-AS160(N) [S149D, 3rd bleed, DSTT (Division of Signal
Transduction Therapy)] was generated at the University of
Dundee using GST (glutathione transferase)–AS1601–280 (human)
fusion protein as the antigen, and column-purified against MBP
(myelin basic protein)–AS1601–280. A sheep antibody against
TBC1D1 was generated at the University of Dundee as described
previously [20]. GLUT1 and GLUT4 antibodies were provided
by Professor Geoffrey Holman (Department of Biology and
Biochemistry, University of Bath, Bath, U.K.). Antibodies that
recognize phosphorylated Ser21/Ser9 on GSK3α/β (glycogen
synthase kinase 3α/β) (catalogue number 9331), phosphorylated
Ser473 on PKB (catalogue number 9271), and anti-PKB
(catalogue number 9272) and anti-PCK2 [recognizing PEPCK
(phosphoenolpyruvate carboxykinase) 2] (catalogue number
6924) were from Cell Signaling Technology. Anti-GSK3α/β
(catalogue number 44-610) was from Invitrogen. Anti-MBP
(catalogue number ab9084) and anti-PCK1 (recognizing
PEPCK1) (catalogue number ab87340) were from Abcam. Anti-
FBP-1 (fructose-1,6-bisphosphatase 1) was from Santa Cruz
Biotechnology (catalogue number sc-32435) and anti-GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) was from Sigma
(catalogue number G8795).
Generation of the AS160-knockout mouse
The AS160T649A knockin mouse, in which the tenth exon
harbouring the T649A mutation is flanked by loxP-Cre excision
sites, was previously generated in our laboratory [12]. The AS160-
knockout mouse was generated by mating the AS160T649A knockin
mouse with the Bal1 mouse line in which Cre recombinase
is expressed in all tissues [21]. The tenth exon of AS160T649A
was excised in the resultant AS160-knockout mouse.
Mouse breeding and genotyping
All animal studies, breeding and husbandry were approved
by the Ethics Committees at the University of Dundee and
Nanjing University. Mice were housed with a light/dark cycle
of 12 h, and free access to food and water unless stated.
Genotyping of AS160-knockout mice and wild-type littermates
was performed by PCR using genomic DNA isolated from an ear
biopsy as described previously [22]. Genotyping of the AS160-
knockout allele was performed by PCR using the primers 5′-
ATCTTGGGGCACTATCAACC-3′ and 5′-TAACCCGTCATA-
CCTGACGAC-3′, and the wild-type allele was genotyped using
the primers 5′-ATCTTGGGGCACTATCAACC-3′ and 5′-CAG-
TGGCATGATCTCTGTGG-3′.
Tissue lysis and immunoprecipitation
Mouse tissues were lysed as described previously [22]. Protein
concentrations were determined using Bradford reagent (Thermo
Scientific).
Anti-AS160(N) antibody (1 μg of antibody/mg of tissue lysate
protein) was used to immunoprecipitate full-length AS160 and
truncated AS1601–609 from various mouse tissues. Briefly, tissue
lysates were incubated with the antibody-coupled Protein G–
Sepharose overnight at 4 ◦C. After washing away non-specific-
binding proteins, the immunoprecipitates were eluted in SDS
sample buffer for subsequent analysis via Western blotting as
described previously [20,23].
Subcellular fractionation of adipose tissue
Subcellular fractionation was carried out as described previously
[12]. Briefly, adipose tissue was homogenized in lysis buffer
[22] with detergent omitted. The unbroken cells were removed
from the homogenates by centrifugation at 500 g for 10 min. The
supernatants were further centrifuged at 10000 g for 12 min to
obtain crude PM (plasma membrane) together with nucleus and
mitochondria, and an intracellular fraction containing cytoplasm
and the GLUT4 storage vesicles. The PM fraction was solubilized
in detergent-containing [1% (v/v) Triton X-100] lysis buffer.
Western blot analysis and quantification
After separation by SDS/PAGE, proteins were immunoblotted
on to nitrocellulose membranes that were blocked in
milk and incubated at 4 ◦C for 16 h using the antibodies
indicated. Signals were detected using horseradish-peroxidase-
conjugated secondary antibodies (Promega) and ECL® (enhanced
chemiluminescence reagent; GE Healthcare). For quantification
of signals, the images were scanned, imported into an Odyssey
imaging system (LI-COR Biosciences) and quantified.
Glucose tolerance test, pyruvate tolerance test and insulin
tolerance test
After mice were deprived of food for 4 h (before the
insulin tolerance test) or overnight (16 h; for glucose and pyruvate
tolerance tests), basal blood glucose levels were measured via tail
bleeding using a Breeze 2 glucometer (Bayer). For glucose and
pyruvate tolerance tests, the mice were intraperitoneally injected
with a bolus of glucose or pyruvate (2 mg of glucose or pyruvate
per g of body weight). For insulin tolerance tests, the mice were
subject to a bolus injection of insulin (0.75 m-units of insulin/g of
body weight). Blood glucose levels were subsequently measured
at the times indicated.
Hyperinsulinaemic–euglycaemic clamp
All procedures required for the hyperinsulinaemic–euglycaemic
clamp were approved by the Vanderbilt University Animal
Care and Use Committee. Catheters were implanted into a carotid
artery and a jugular vein of mice for sampling and infusions
respectively 5 days before the study [24]. Insulin clamps were
performed on mice fasted for 5 h. [3-3H]Glucose was primed
(2.4 μCi) and continuously infused for a 90-min equilibration
c© The Authors Journal compilation c© 2013 Biochemical Society
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Figure 1 Generation and basic characterization of the AS160-knockout mouse
(A) AS160 expression in various tissues. Various tissues were removed from 8-week-old male mice. Full-length AS160 proteins were measured in 40 μg of tissue lysates using the commercial
anti-AS160(C) antibody that was raised against a C-terminal peptide of AS160. (B) Characterization of the anti-AS160(N) antibody. MBP-tagged human AS160 proteins (full-length and fragments)
were expressed in and purified from Escherichia coli, and subjected to Western blotting analysis (300 ng/lane). In the left-hand panel, the anti-MBP antibody was used to detect the MBP-tagged
recombinant proteins. In the right-hand panel, the anti-AS160 (N) antibody was used for detection. (C) Expression of full-length AS160 and truncated AS1601–609 in soleus muscle. Soleus muscle
was removed from 8-week-old male mice. Full-length AS160 proteins and truncated AS1601–609 fragment were measured in 40 μg of soleus lysates using the anti-AS160(N) antibody that is
raised agaist the N-terminus (residues 1–280) of human AS160. (D) Immunoprecipitation of full-length AS160 and truncated AS1601–609 from tissue lysates of gastrocnemius (GAS) muscle.
GAS muscle was removed from 8-week-old male mice. Full-length AS160 proteins and truncated AS1601–609 fragment (if the latter had been present) were immunoprecipitated from 500 μg
of GAS lysates using the anti-AS160(N) antibody. The immunoprecipitates were analysed using Western blotting with the anti-AS160(N) antibody (used at 1 μg/ml at 4◦C overnight). (E) Oxygen
consumption during a metabolic cage study. The AS160-knockout and wild-type male mice (8 weeks old) were monitored using an Oxymax/CLAMS system (Columbus Instruments). The data are
given as the means +− S.E.M. (n = 6–7). (F) Heat production during a metabolic cage study. The AS160-knockout and wild-type male mice (8 weeks old) were monitored using an Oxymax/CLAMS
system (Columbus Instruments). The data are given as the means +− S.E.M. (n = 6–7). * P < 0.05. For (B–D) the molecular mass in kDa is indicated on the left-hand side. IB, immunoblot; IP,
immunoprecipitation; KO, knockout; WT, wild-type.
period (0.04 μCi/min) and a 2-h clamp period (0.12 μCi/min).
Baseline blood or plasma parameters were determined as the
mean of values obtained in blood samples collected at − 15
and − 5 min. At time 0, insulin infusion (2.5 m-units/kg of body
weight per min) was started and continued for 165 min. Blood
glucose was clamped using a variable rate of glucose infusion,
which was adjusted based on the measurement of blood glucose
at 10 min intervals. Mice received heparinized saline-washed
erythrocytes from donors at 5 μl/min to prevent a fall in
haematocrit. Insulin clamps were validated by assessment of
blood glucose over time. Blood was taken at 80–120 min for the
determination of [3-3H]glucose. Clamp insulin was determined at
t = 100 and 120 min. At 120 min, 13 μCi of 2-[14C]deoxyglucose
(abbreviated to [14C]2DG) was administered as an intravenous
bolus. Blood was taken at 2, 15, 25 and 35 min after the bolus for
the determination of [14C]2DG. After the last sample, mice were
anaesthetized and tissues were collected.
Insulin clamp plasma and tissue sample processing
Plasma insulin was determined by ELISA (Millipore).
Radioactivity of [3-3H]glucose, [14C]2DG and [14C]2DG-6-
c© The Authors Journal compilation c© 2013 Biochemical Society
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Table 1 Basic characterization of the AS160-knockout mouse
Plasma insulin, blood glucose, adiponectin and NEFA [non-esterified (‘free’) fatty acid] concentrations were measured in 10–12-week-old male mice after fasting (5 h in the case of NEFAs, and 16 h
for plasma insulin and adiponectin, and blood glucose measurements) and random-fed conditions. Glycogen levels were determined in TA muscle from 6-week-old mice after partial fasting (5 h).
Values are given as means +− S.E.M. from at least six animals. n.d., not determined. *P < 0.05 and §P = 0.094.
Fasted Fed
Measurement Wild-type Knockout Wild-type Knockout
Insulin (ng/ml) 0.226 +− 0.010 0.232 +− 0.019 0.930 +− 0.169 0.728 +− 0.037
Blood glucose (mM) 7.3 +− 0.4 5.9 +− 0.3* 9.8 +− 0.2 9.0 +− 0.4
Adiponectin (ng/ml) 10.0 +− 0.8 8.5 +− 0.4§ 11.4 +− 0.3 9.2 +− 0.4*
NEFA (mM) 1.062 +− 0.066 1.220 +− 0.106 0.898 +− 0.062 0.938 +− 0.086
Triacylglycerol (mM) n.d. n.d. 0.704 +− 0.037 0.709 +− 0.065
Muscle glycogen (μmol/g) 15.8 +− 2.6 16.6 +− 2.8 n.d. n.d.
phosphate in plasma and tissue samples were determined
by liquid-scintillation counting [25]. Glucose appearance and
disappearance rates were determined using non-steady-state
equations [26]. Endogenous glucose production was determined
by subtracting the GIR (glucose infusion rate) from the total
glucose production. The glucose metabolic index was calculated
as described previously [27].
Indirect calorimetry measurement
Male mice at 8 weeks of age were individually housed in and
adapted to metabolic cages (Columbus Instruments) for 24 h
before indirect calorimetry measurements. Oxygen consumption
( ˙V O2), carbon dioxide production ( ˙V CO2), physical activity
(XAMB) and food intake were monitored using Oxymax/CLAMS
(Columbus Instruments). Data were collected for 2 days and
averaged for these 2 days. The RER (respiratory exchange ratio)
is calculated as:
RER = ˙V CO2/ ˙V CO2
Heat production (kcal/unit time; 1 kcal = 4.184 kJ) was calculated
using the following equation:
Heat = (3.815 + 1.232 × RER)× ˙V O2
Muscle incubation and glucose uptake ex vivo
Soleus or EDL (extensor digitorum longus) muscles were isolated
and incubated with or without insulin in KRB (Krebs–Ringer
bicarbonate) buffer for 50 min as described previously [12]. After
incubation, the muscles were either snap-frozen in liquid nitrogen
to study signalling proteins or used for the glucose-uptake assay
as described previously [28]. After glucose uptake, the muscles
were snap-frozen, weighed and processed as described previously
[28]. Radioisotopes in the muscles were counted using a Tri-Carb
2800TR scintillation counter (PerkinElmer).
Glucose uptake in primary adipocytes
Primary adipocytes were isolated from epididymal fat pads
as described previously [12]. Cells were incubated with or
without insulin at 37 ◦C for 30 min. Glucose uptake was
subsequently carried out at 37 ◦C for 30 min in the presence
or absence of insulin, and stopped by adding cytochalasin B
as described previously [12]. Cell suspension was centrifuged
through dinonylphtalate oil and used for scintillation counting
with a Tri-Carb 2800TR scintillation counter (PerkinElmer).
Statistical analysis
Data analysis was carried out using Student’s t test, and
differences were considered statistically significant at P < 0.05.
RESULTS
Generation of an AS160-knockout mouse
We previously reported the generation of an AS160T649A knockin
mouse in which the tenth exon harbouring a T649A mutation
is flanked by loxP-Cre excision sites [12]. This strategy allows
AS160-knockout mice to be generated by mating the AS160T649A
knockin mouse with the Bal1 mouse line that expresses Cre
recombinase in all tissues [21]. The tenth exon of the AS160
T649A allele was excised in the offspring of such matings
(depicted in Supplementary Figure S1A at http://www.biochemj.
org/bj/449/bj4490479add.htm), resulting in a shift in the open
reading frame of AS160. Theoretically, this frame-shift could
produce a peptide spanning amino acids 1–609 of AS160 plus
a short sequence of HCPVSPAHVQGE in the AS160-knockout
mouse. The expression of full-length AS160 was decreased in
the tissues from the heterozygous AS160-knockout mouse, and
undetectable in the tissues from the homozygous AS160-knockout
mouse using a commercial AS160 antibody raised against
a C-terminal peptide of AS160, here termed anti-AS160(C)
(Figure 1A). To search for expression of the theoretical truncated
AS1601–609, we also generated an antibody that specifically
recognized the N-terminus of AS160 (amino acids 1–280),
termed anti-AS160(N) (Figure 1B). Using this antibody, we failed
to find any AS1601–609 fragment in extracts of soleus muscle
from the AS160-knockout mouse (Figure 1C). Moreover, the
anti-AS160(N) antibody could immunoprecipitate the full-length
AS160 protein from various tissues of the wild-type mouse,
less full-length protein and no detectable AS1601–609 fragment
from various tissues of the heterozygous AS160-knockout mouse,
and more importantly no detectable full-length and AS1601–609
fragment from various tissues of the homozygous AS160-
knockout mouse (Figure 1D and Supplementary Figures 1B–1D).
These data showed that the AS160-knockout mouse generated
in the present study was suitable for addressing the effects of
loss-of-function of AS160 on glucose metabolism.
Basic characterization of the AS160-knockout mouse
The AS160-knockout mouse was viable and exhibited no
gross physical abnormalities. Body weight gain of the
AS160-knockout mouse was normal within the monitoring
period (Supplementary Figure S2 at http://www.biochemj.org/
c© The Authors Journal compilation c© 2013 Biochemical Society
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Figure 2 Insulin-stimulated phosphorylation of GSK3 and PKB in muscle and adipose tissue
Soleus (A) and EDL (B) muscles isolated from 8-week-old mice were incubated in the absence or presence of insulin (0.1 or 50 m-units/ml) for 50 min. Adipose tissue (C) was collected from
8-week-old mice that were intraperitoneally injected with 150 m-units/g insulin or saline for 20 min. Full-length AS160 was detected in 40 μg of muscle lysates using the commercial anti-AS160
antibody that recognizes the C-terminus of AS160. The phosphorylation of GSK3 and PKB, and total GSK3, PKB and TBC1D1, and GAPDH were determined in 40 μg of muscle or adipose lysates
by using the respective phospho-specific antibodies or total antibodies indicated in the Materials and methods section.
Figure 3 Glucose clearance in the AS160-knockout mouse after intraperitoneal injection with glucose or insulin
(A) Glucose tolerance test of male mice at 8 weeks of age. The values show the glucose area under the curve during the glucose tolerance test. The data are given as the means +− S.E.M. (n = 5–6).
(B) Glucose tolerance test of male mice at 12 weeks of age. The values show the glucose area under the curve during the glucose tolerance test. The data are given as the means +− S.E.M. (n = 7).
(C) Insulin tolerance test of male mice at 7–8 weeks of age. The values show the glucose area above the curve during the insulin tolerance test. The data are given as the means +− S.E.M. (n = 6–7).
*P < 0.05. (D) Insulin tolerance test of male mice at 16–17 weeks of age. The values show the glucose area above the curve during the insulin tolerance test. The data are given as the means +− S.E.M.
(n = 8). *P < 0.05. AUC, area under the curve; KO, knockout; WT, wild-type.
bj/449/bj4490479add.htm). However, blood glucose levels under
both randomly fed and fasted conditions were lower, whereas
plasma non-esterified (free) fatty acid levels were slightly higher
under fasted conditions in the AS160-knockout mice compared
with the wild-type littermates (Table 1). There was no change in
the plasma triacylglycerol levels under randomly fed conditions,
and muscle glycogen levels were also normal in the AS160-
knockout mouse (Table 1). The plasma insulin level was normal
under fasted conditions, and slightly lower under randomly fed
conditions in the AS160-knockout mouse (Table 1). The plasma
adiponectin level was slightly lower under fasted conditions,
and significantly lower under randomly fed conditions in the
AS160-knockout mouse (Table 1). The AS160-knockout mouse
had normal food intake and physical activities (Supplementary
Figures S1G and S1H), but a decreased rate of energy expenditure
as shown by lower rates of oxygen consumption and heat
production (Figures 1E and 1F).
Insulin signalling in muscle and adipose tissue is normal in the
AS160-knockout mouse
Insulin signalling was analysed in isolated muscles from the
AS160-knockout mice and wild-type littermates using two doses
of insulin (submaximal dose, 0.1 m-units/ml; maximal dose, 50
m-units/ml). Phosphorylation of PKB and its substrate GSK3α/β
was normal in soleus muscle from the AS160-knockout mouse
c© The Authors Journal compilation c© 2013 Biochemical Society
484 H. Y. Wang and others
Figure 4 GIR, endogenous glucose production (endoRa), whole-body glucose disappearance (Rd) and tissue glucose uptake during hyperinsulinaemic–
euglycaemic clamp
(A) GIR during euglycaemic clamp in the AS160-knockout and wild-type male mice (16 weeks old). Data are given as means +− S.E.M. for six (wild-type) or ten (knockout) mice. *P < 0.05. (B)
Steady-state GIR obtained from averaged rates of 80–120 min of hyperinsulinaemic–euglycaemic clamps in the AS160-knockout mice and wild-type littermates. Data are given as means +− S.E.M.
for six (wild-type) or ten (knockout) mice. *P < 0.05. (C) Endogenous glucose appearance rates (endoRa) during basal conditions and euglycaemic clamps. Basal endoRa is obtained from averaged
values at t = − 10 and 0 min before onset of insulin infusion. Clamp endoRa is obtained from averaged rates of 80–120 min of euglycaemic clamps. Data are given as means +− S.E.M. for six
(wild-type) or ten (knockout) mice. *P < 0.05. (D) Whole-body glucose disappearance rates (Rd) during basal conditions and euglycaemic clamps. Basal Rd is obtained from averaged values at
t = − 10 and 0 min before onset of insulin infusion. Clamp Rd is obtained from averaged rates of 80–120 min of euglycaemic clamps. Data are given as means +− S.E.M. for six (wild-type) or ten
(knockout) mice. *P < 0.05. (E and F) Insulin-stimulated glucose uptake during euglycaemic clamps in skeletal muscle [vastus lateralis (E) and soleus (F)] from the AS160-knockout mouse and
wild-type littermates. Data are given as means +− S.E.M. for six (wild-type) or ten (knockout) mice. *P < 0.05. KO, knockout; WT, wild-type.
with both doses of insulin (Figure 2A), suggesting that proximal
insulin signalling was intact in the AS160-knockout mouse.
Moreover, the expression level of the related RabGAP TBC1D1
was not altered in soleus muscle from the AS160-knockout
mouse (Figure 2A). Similar results were obtained in isolated EDL
muscle (Figure 2B). Insulin-stimulated phosphorylation of PKB
and GSK3α/β was also normal in adipose tissue from the AS160-
knockout mouse (Figure 2C). Taken together, these data suggest
that the AS160-knockout mouse described in the present study is
a useful model to study the effect of AS160 deletion on glucose
metabolism.
The AS160-knockout mouse is glucose-tolerant but exhibits
reduced insulin sensitivity
We next investigated the effects of knocking out AS160 on
whole-body glucose homoeostasis. The AS160-knockout mice
and wild-type littermates were fasted overnight (16 h) and
injected intraperitoneally with a bolus of glucose (2 mg of
glucose/g of body weight). The blood glucose levels reached
similar peaks and then declined at similar rates in the two
genotypes at ages of 2 and 3 months (Figures 3A and 3B).
Plasma insulin levels after glucose injection were normal in the
c© The Authors Journal compilation c© 2013 Biochemical Society
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Figure 5 Pyruvate tolerance test and hepatic PEPCK expression
(A) Pyruvate tolerance test of the AS160-knockout and wild-type male mice at 9–10 weeks of age. After deprivation of food for 16 h (overnight), the mice were intraperitoneally injected with a bolus
of pyruvate (2 mg/g of body weight). At zero time, and at the indicated times after injection, blood glucose levels were determined with a Breeze 2 glucometer (Bayer). The incremental area under
the curve (IncAUC) was calculated. Data are given as the means +− S.E.M. (n = 4 for each genotype). *P < 0.05. (B–D) PEPCK protein expression in liver from the AS160-knockout and wild-type
mice. Liver lysates (40 μg) were separated by SDS/PAGE and subject to Western blot analysis. The levels of cytosolic (anti-PCK-1) and mitochondrial (anti-PCK-2) isoforms of PEPCK, FBP-1,
glycogen synthase (GS), glycogen phosphorylase (GP) and GAPDH were measured using the antibodies indicated. The PEPCK signals were quantified and normalized with GAPDH. Data are given
as means +− S.E.M. (n = 4). *P < 0.05. A.U., arbitrary unit; KO, knockout; WT, wild-type.
AS160-knockout mouse (Supplementary Figure S3 at http://www.
biochemj.org/bj/449/bj4490479add.htm). The AS160-knockout
mice and wild-type littermates were partially fasted for 4 h and
then intraperitoneally injected with a bolus of insulin (0.75 m-
units/g of body weight). Consistent with the aforementioned data
(Table 1), the blood glucose level was significantly lower in the
AS160-knockout mice than in wild-type littermates after their
4 h fast. Interestingly, insulin did not decrease blood glucose
levels in the AS160-knockout mice as efficiently as in the wild-
type littermate controls at 2 and 4 months (Figures 3C and 3D),
suggesting that the AS160-knockout mice are insulin resistant.
To identify the site(s) of insulin resistance in the
AS160-knockout mouse, we carried out a hyperinsulinaemic–
euglycaemic clamp. In response to constant insulin infusion,
glucose was infused at a variable rate to maintain blood glucose
levels that were tightly controlled at similar levels (∼5.5 mM) in
the AS160-knockout and wild-type mice (Supplementary Figure
S4A at http://www.biochemj.org/bj/449/bj4490479add.htm).
Plasma insulin levels were comparable in the AS160-knockout
and wild-type mice before the clamp, and were significantly
elevated to a similar extent in the two genotypes during the
clamp (Supplemenatry Figure S4B). The glucose infusion rates
required to maintain euglycaemia were significantly lower in the
AS160-knockout mice than the wild-type littermates (Figures 4A
and 4B), again suggesting that the AS160-knockout mice were
insulin-resistant, consistent with the reduced insulin sensitivity
revealed by the insulin tolerance test. The rates of endogenous
glucose production were comparable in the two genotypes
before the clamp; however, they were significantly higher in the
AS160-knockout mice than the wild-type littermates during
the clamp (Figure 4C), suggesting that insulin-induced
suppression of hepatic glucose production was impaired in the
AS160-knockout mice. The rates of glucose disposal were normal
in the AS160-knockout mice before the clamp, but significantly
lower in the AS160-knockout mice compared with wild-type
littermates during the clamp (Figure 4D). Consistent with skeletal
muscle accounting for the majority of glucose disposal under
such conditions, the glucose uptake rates during the clamp were
significantly lower in skeletal muscle of the AS160-knockout mice
than the wild-type littermates (Figure 4E and 4F). Taken together,
impaired muscle and liver insulin action accounts for the reduced
whole-body insulin sensitivity in the AS160-knockout mouse.
The AS160-knockout mouse has altered hepatic function and
gluconeogenetic enzyme expression
To investigate the mechanisms underlying the hepatic insulin
resistance in the AS160-knockout mouse, we carried out
a pyruvate tolerance test in which the mice were injected
intraperitoneally with a bolus of pyruvate (2 mg of pyruvate/g
of body weight) after deprivation of food for 16 h (overnight).
The AS160-knockout mice were intolerant to pyruvate challenge
(Figure 5A), indicating they might have increased hepatic
gluconeogenesis. In line with this, the expression of both
cytosolic and mitochondrial isoforms of PEPCK, a key enzyme
in gluconeogenesis, were significantly increased in liver from the
AS160-knockout mice (Figures 5B–5D).
Tissue-dependent impairment of glucose uptake in primary
adipocytes and isolated skeletal muscle from the AS160-knockout
mouse
To elucidate the mechanisms underlying the diminished glucose
disposal and decreased insulin sensitivity in the AS160-knockout
c© The Authors Journal compilation c© 2013 Biochemical Society
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Figure 6 Insulin-stimulated glucose uptake in primary adipocytes and
muscle ex vivo
(A) Insulin-stimulated glucose uptake in primary adipocytes. The primary adipocytes isolated
from epididymal fat pads of male mice (16 weeks old) were stimulated with or without 16.7
m-units/ml insulin for 30 min and used for the glucose uptake assay. Data are given as
means +− S.E.M. (n = 9–10). *P < 0.05. (B) Insulin-stimulated glucose uptake in soleus muscle
ex vivo. Soleus muscle isolated from the AS160-knockout and wild-type mice (10–16 weeks old)
was stimulated with or without 0.1 m-units/ml insulin and used for the glucose uptake assay.
Data are given as means +− S.E.M. (n = 13–14). *P < 0.05. (C) Insulin-stimulated glucose
uptake in EDL muscle ex vivo. EDL muscle isolated from the AS160-knockout and wild-type
mice (6–11 weeks old) was stimulated with or without 0.5 m-units/ml insulin and used for
the glucose uptake assay. Data are given as means +− S.E.M. (n = 5–7). KO, knockout; WT,
wild-type.
mice, we next measured the rate of glucose uptake into primary
adipocytes and isolated skeletal muscle. In primary adipocytes
isolated from epididymal fat pad, glucose uptake under basal
conditions was significantly increased by nearly 40%, whereas
insulin-stimulated glucose uptake was decreased by 50% in
AS160-knockout cells compared with wild-type cells (Figure 6A).
In isolated soleus muscle, glucose uptake under unstimulated con-
ditions was comparable in the AS160-knockout and wild-type lit-
termates (Figure 6B). Insulin stimulated glucose uptake by nearly
2-fold in isolated soleus muscle from the wild-type mice, whereas
the insulin response was almost completely blunted in soleus
muscle from the AS160-knockout mice (Figure 6B). In isolated
EDL muscle, glucose uptake under unstimulated conditions was
also comparable in the two genotypes (Figure 6C). In contrast
with isolated soleus muscle, glucose uptake was stimulated by
insulin to a similar extent (∼60%) in isolated EDL muscles from
the wild-type and AS160-knockout mice (Figure 6C).
Tissue-dependent impairment of GLUT4 expression in adipose
tissue and skeletal muscle from the AS160-knockout mouse
To gain insights into the changes in glucose uptake in
primary adipocytes and skeletal muscle, we determined the
expression levels of GLUT4 in adipose tissue and skeletal
muscle, which is the major mediator of insulin-stimulated glucose
uptake in these tissues. Interestingly, the GLUT4 levels were
significantly decreased in adipose tissue (epididymal fat), soleus,
gastrocnemius and vastus muscle from the AS160-knockout
mouse compared with the wild-type littermates, whereas they
were comparable in EDL and TA (tibialis anterior) muscle from
the two genotypes (Figures 7A–7F). The GLUT4 levels correlated
with the selective impairment of glucose uptake in primary
adipocytes, and soleus, vastus and EDL muscle. In contrast,
GLUT1 levels were normal in both adipose tissue and skeletal
muscle (Supplementary Figure S5 at http://www.biochemj.org/
bj/449/bj4490479add.htm).
Since AS160 plays a key role in regulating GLUT4 trafficking,
we next performed subcellular fractionation of adipose tissue to
investigate the effect of AS160 deficiency on insulin-stimulated
GLUT4 translocation. The GLUT4 levels on the PM were lower
in adipose tissue from the AS160-knockout mice at both basal and
insulin-stimulated states (Figures 7G and 7H), whereas its fold-
increase upon insulin stimulation was similar in the two genotypes
(∼2-fold in both genotypes; Figures 7G and 7H), suggesting
that AS160 deficiency does not impair insulin-stimulated GLUT4
translocation itself, and the lower GLUT4 levels on the PM and
glucose uptake upon insulin stimulation were most likely due to
the decreased expression levels of GLUT4 in the AS160-knockout
mice.
DISCUSSION
In the present study, we generated an AS160-knockout mouse
model to study the effects of AS160 deletion on glucose
homoeostasis in mouse, which reveals similarities and differences
between the AS160-knockout mouse and the human patients
bearing the AS160 truncation mutation [19]. For example, both the
AS160-knockout mouse and humans with the AS160 truncation
developed insulin resistance. Unlike the human patient who
displays postprandial hyperinsulinaemia, the AS160-knockout
mouse did not develop postprandial hyperinsulinaemia, but had
rather normal plasma insulin levels. Detailed investigation of the
AS160-knockout mouse revealed the mechanisms underlying
the insulin resistance caused by AS160 deletion. Measurement
of whole-body glucose fluxes and analyses of skeletal muscle and
adipose tissue uncovered new aspects of AS160 in regulation of
glucose homoeostasis in these tissues.
Experimentally, a peptide (amino acids 1–362) of AS160,
corresponding to the truncated protein that might be expressed
in the human patients with the AS160-R363X mutation, was
able to inhibit insulin-stimulated GLUT4 translocation when
overexpressed in 3T3-L1 adipocytes [19]. Recently, it has also
been shown that a longer peptide (amino acids 1–532) of
AS160 could inhibit insulin-stimulated GLUT4 vesicle fusion
with the plasma membrane in vitro [29]. In both cases, the
inhibitory effects of these two peptides of AS160 on GLUT4
translocation or GLUT4 vesicle fusion were proposed to be
mediated through dimerization with the full-length AS160 and
therefore interference with its function in a dominant-negative
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Figure 7 Total and PM-associated GLUT4 levels in adipose tissue and skeletal muscle
(A–F) Total GLUT4 levels in adipose tissue and various skeletal muscles from the AS160-knockout and wild-type mice (8 weeks old). GLUT4 proteins were detected in 40 μg of total lysates of
adipose tissue, and skeletal muscle using an anti-GLUT4 antibody (A, C and E) and the signals were quantified (B, D and F). Data are given as means +− S.E.M. (B, n = 4; D, n = 7–9; F, n = 6).
*P < 0.05. (G–H) GLUT4 levels on the PM of adipose tissue. Adipose tissue was collected from 8-week-old mice that were intraperitoneally injected with 150 m-units/g insulin or saline (basal) for
20 min. Subcellular fractionation of adipose tissue was carried out as described in Materials and methods section. The GLUT4 levels in the PM fraction was determined via Western blot analysis
using an anti-GLUT4 antibody (G) and the signals were quantified (H). Data are given as means +− S.E.M. (n = 3–4). *P < 0.05; a! indicates P < 0.05 compared with WT (insulin). A.U., arbitrary
unit; GAS, gastrocnemius; KO, knockout; WT, wild-type.
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manner [19,29]. In the latter case, the peptide dimerized with the
full-length AS160 and consequently disrupted its interaction with
14-3-3 protein [29], which plays an important role in insulin-
stimulated GLUT4 trafficking [12]. However, these mechanisms
cannot explain the lower insulin-stimulated glucose uptake in
primary adipocytes and certain types of skeletal muscle from the
AS160-knockout mouse (Figures 4E, 4F, 6A and 6B) because
the theoretical truncated peptide of AS160 was not detectable
and there was no full-length AS160 in the homozygous AS160-
knockout mouse (Figures 1B–1D).
We found that the GLUT4 levels were decreased in adipose
tissue, and soleus, gastrocnemius and vastus muscle, whereas
they remained normal in EDL and TA muscle in the AS160-
knockout mice (Figures 7A–7F). This tissue-dependent effect on
GLUT4 levels in adipose tissue and skeletal muscle correlates
with the changes in insulin-stimulated glucose uptake in primary
adipocytes and various types of skeletal muscle (Figures 4E–4F
and 6A–6C), suggesting that the decreased glucose uptake in
response to insulin in primary adipocytes, and soleus and vastus
muscle from the AS160-knockout mouse is most probably caused
by the lower levels of GLUT4 in these cells and tissues. During
the revision of the present paper, another AS160-knockout mouse
model was reported, in which GLUT4 levels were also decreased
in a similar tissue-dependent fashion [30]. But why does the
deletion of AS160 affect the GLUT4 levels in a tissue-dependent
manner? We do not know the answer yet, although we have
noticed that the tissue-dependent effect of AS160 deletion on
GLUT4 levels correlates with the expression levels of AS160
in wild-type mice. The expression levels of AS160 are higher in
adipose tissue, and soleus and vastus muscle than that in TA and
EDL muscle (Supplementary Figure S6 at http://www.biochemj.
org/bj/449/bj4490479add.htm). The effect of AS160 deletion on
GLUT4 levels is reminiscent of the effect of a related RabGAP,
TBC1D1, whose deletion in mouse also results in a decrease in
GLUT4 levels in skeletal muscle [31]. In contrast, GLUT4 levels
were elevated in muscle and adipose tissue in the AS160T649A
knockin mouse [12]. These observations raise two questions to
be addressed in the future. First, how does manipulation of these
two related RabGAPs, namely AS160 and TBC1D1, affect the
GLUT4 levels? Another critical question is whether deletion
of AS160 and TBC1D1 affect the same or different pools of
GLUT4.
The decreased GLUT4 levels also affected the in vivo glucose
uptake in skeletal muscle (Figures 4E and 4F) which, together
with impaired insulin-induced suppression of hepatic glucose
production, contributed to the decreased insulin sensitivity in
the AS160-knockout mouse (Figures 2C, 2D and 4A). However,
one puzzle is that the insulin resistance in skeletal muscle and
liver did not result in glucose intolerance and hyperinsulinaemia
in the AS160-knockout mouse. The AS160-knockout mouse
displayed normal plasma insulin levels after intraperitoneal
injection of glucose (Supplementary Figure S3), suggesting that
there was no compensation from plasma insulin levels to regulate
glucose homoeostasis in the AS160-knockout mouse after glucose
injection. Another conundrum is that blood glucose levels under
both randomly fed and fasting conditions were lower, despite the
insulin resistance and decreased GLUT4 levels, in the AS160-
knockout mouse. These two puzzles suggest that there must be
a mechanism only operating under conditions (such as feeding
and glucose injection) that elevate plasma insulin levels within
physiological ranges via insulin secretion from pancreatic β-
cells, but not under conditions (such as insulin tolerance test
and insulin clamp) that result in hyperinsulinaemia independent
of insulin secretion from pancreatic β-cells. Nevertheless, these
metabolic changes in the AS160-knockout mouse are reminiscent
of the phenotype of the muscle-specific insulin-receptor-knockout
mouse that is glucose tolerant and maintains euglycaemia, but
displays insulin resistance in euglyacemic clamp studies [32,33].
While AS160 is expressed in most tissues analysed, the protein
was undetectable in liver extracts (Supplementary Figure S6),
although an AS160-derived peptide was identified in a digest
of 14-3-3 affinity-purified proteins from liver (M. Tinti and
C. MacKintosh, unpublished work). Nevertheless, liver in the
AS160-knockout mouse developed insulin resistance (Figure 4B),
suggesting that either there is an important ‘trace’ expression of
AS160 in liver, or perhaps, more likely, there is tissue ‘cross-
talk’ in the AS160-knockout mouse. Insulin resistance caused by
tissue ‘cross-talk’ is commonly found in GLUT4-knockout mouse
models. For instance, in the adipose-specific GLUT4-knockout
mouse, liver and skeletal muscle also develop insulin resistance
that was speculated to be caused by an unidentified adipocyte-
derived molecule [34,35]. In the muscle-specific GLUT4-
knockout mouse, insulin actions in adipose tissue and liver are
also impaired, which is at least partly due to glucose toxicity
[35–37]. In contrast, overexpression of GLUT4 in muscle and fat
causes increased hepatic insulin actions in the fasted transgenic
mice [38]. Since the GLUT4 levels were decreased in certain
types of muscle and adipose tissue in the AS160-knockout mouse,
one possibility is that adipose tissue with the decreased GLUT4
levels might cross-talk with the liver and result in hepatic insulin
resistance in the AS160-knockout mouse. Another possibility
is that AS160 in certain tissue(s) might modulate a messenger
that can cross-talk with the liver and regulate hepatic insulin
sensitivity, and deletion of AS160 might disrupt such cross-talk.
In support of this notion, the levels of adiponectin, which is a
known factor modulating insulin sensitivity [39], were lower in
the plasma of the AS160-knockout mouse (Table 1), although the
importance of adiponectin in the development of hepatic insulin
resistance in the AS160-knockout mouse is still to be investigated.
In summary, deletion of AS160 has an impact on glucose
homoeostasis in mouse by: (i) decreasing GLUT4 levels in certain
types of skeletal muscle and adipose tissue, thus resulting in
a lower glucose uptake rate and (ii) causing hepatic insulin
resistance through an unknown inter-organ communication
process. Consequently, these effects render the AS160-knockout
mouse less sensitive to insulin.
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Figure S1 Generation and basic characterization of the AS160-knockout mouse
(A) Strategy for generating the AS160-knockout mouse. The diagram shows the conditional and conventional allele of AS160. The tenth exon harbouring the T649A mutation is flanked by loxP sites.
The AS160-knockout mouse was generated by mating the AS160T649A knockin mouse with the Bal1 mouse line that expresses Cre recombinase in all tissues. The tenth exon harbouring the T649A
mutation was excised through loxP-Cre recombination. (B–D) Immunoprecipitation of full-length AS160 and truncated AS1601–609 from tissue lysates. Tissues were removed from 8-week-old male
mice. Full-length AS160 proteins and truncated AS1601–609 fragment (if the latter had been present) were immunoprecipitated from 60μg of soleus lysates, 400μg of adipose lysates or 400μg
of heart lysates using the anti-AS160(N) antibody. The immunoprecipitates were analysed via Western blotting with the anti-AS160(N) antibody (used at 1μg/ml at 4◦C overnight). The molecular
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Figure S2 Body weight of the AS160-knockout mice
Wild-type ( + / + ), heterozygous ( + / − ) and homozygous ( − / − ) AS160-knockout male
mice were weighed once per week from 7 to 23 weeks of age.
Figure S3 Plasma insulin levels during a glucose tolerance test
The data are given as the mean (+−S.E.M.) from seven to eight male mice (12–13 weeks old).
KO, knockout; WT, wild-type.
mass in kDa is indicated on the left-hand side. (E–H) Indirect calorimetry measurement. The AS160-knockout and wild-type male mice (8-week-old) were monitored using an Oxymax/CLAMS
system (Columbus Instruments). The data are given as the means +− S.E.M. (n = 6–7) for V˙ CO2 (CO2 production) RER, X AMB (ambulatory activity) and feed intake, as indicated. IB, immunoblot; IP,
immunoprecipitate; KO, knockout; WT, wild-type.
Figure S4 Blood glucose and plasma insulin levels during
hyperinsulinaemic–euglycaemic clamp
(A) Blood glucose levels during euglycaemic clamp in the AS160-knockout and wild-type
male mice (16 weeks old). Data are given as means +− S.E.M. for six (wild-type) or ten
(knockout) mice. (B) Plasma insulin levels before and after hyperinsulinaemic–euglycaemic
clamps in the AS160-knockout mice and wild-type littermates. Data are given as means +− S.E.M.
for six (wild-type) or ten (knockout) mice. (C) Plasma glucose specific activity during t = 80
to 120 min of the hyperinsulinaemic–euglycaemic clamp period. The slope of the relationship
between glucose specific activity and time was not significantly different from 0, demonstrating
that this variable was in a steady state. Data are given as means +− S.E.M. for six (wild-type) or
ten (knockout) mice. KO, knockout; WT, wild-type.
c© The Authors Journal compilation c© 2013 Biochemical Society
H. Y. Wang and others
Figure S5 GLUT1 protein levels in adipose tissue and skeletal muscle
GLUT1 proteins were detected in 40μg of total lysates in adipose tissue and skeletal muscle
[gastrocnemius (GAS)] from the AS160-knockout and wild-type mice (8 weeks old) using an
anti-GLUT1 antibody.
Figure S6 The expression pattern of AS160 in mouse tissues
The expression of AS160 was determined in tissues from 8-week-old male wild-type mice.
Tissue lysates (40μg) were subjected to Western blotting analysis, and AS160 was detected
using the anti-AS160(C) antibody. GAS, gastrocnemius.
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